1. P014 Interim analysis of ELEANOR (n = 200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib. (April 2023) Authors: Bartsch, R.; Harbeck, N.; Wrobel, D.; Zaiss, M.; Terhaag, J.; Guth, D.; Distelrath, A.; Wuerstlein, R.; Zahn, M.-O.; Lüftner, D.; Schwitter, M.; Balic, M.; Jackisch, C.; Müller, V.; Rinnerthaler, G.; Schmidt, M.; Zaman, K.; Schinköthe, T.; Gorray, M.; Breitenstein, U. Journal: Breast Issue: Volume 68(2023) Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗